C
Charles L. Loprinzi
Researcher at Mayo Clinic
Publications - 579
Citations - 38967
Charles L. Loprinzi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 96, co-authored 557 publications receiving 34416 citations. Previous affiliations of Charles L. Loprinzi include McGill University & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Definition and classification of cancer cachexia: an international consensus
Kenneth C. H. Fearon,Florian Strasser,Stefan D. Anker,Ingvar Bosaeus,Eduardo Bruera,Robin L. Fainsinger,Aminah Jatoi,Charles L. Loprinzi,Neil MacDonald,Giovanni Mantovani,Mellar P. Davis,Maurizio Muscaritoli,Faith D. Ottery,Lukas Radbruch,Paula Ravasco,Declan Walsh,Andrew Wilcock,Stein Kaasa,Vickie E. Baracos +18 more
TL;DR: A framework exists on a framework for the definition and classification of cancer cachexia, a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.
Journal ArticleDOI
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Robert S. Sandler,Susan Halabi,John A. Baron,Susan Budinger,Electra D. Paskett,Roger Keresztes,Nicholas J. Petrelli,J. Marc Pipas,Daniel D. Karp,Charles L. Loprinzi,Gideon Steinbach,Richard L. Schilsky +11 more
TL;DR: In this paper, the authors conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas, which was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis.
Journal ArticleDOI
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Sharlene Gill,Charles L. Loprinzi,Daniel J. Sargent,Stephan D. Thomé,Steven R. Alberts,Daniel G. Haller,Jacqueline Benedetti,Guido Francini,Lois E. Shepherd,Jean Francois Seitz,Roberto Labianca,Wei Chen,Stephen S. Cha,Michael P. Heldebrant,Richard M. Goldberg +14 more
TL;DR: Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade, which may improve patients' and physicians' understanding of the potential benefits of adjuvant therapy.
Journal ArticleDOI
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more
TL;DR: Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptylines HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPn treatment options.
Journal ArticleDOI
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
Charles L. Loprinzi,John W. Kugler,Jeff A. Sloan,James A. Mailliard,Beth I. LaVasseur,Debra L. Barton,Paul J. Novotny,Shaker R. Dakhil,Kate Rodger,Teresa A. Rummans,Bradley J. Christensen +10 more
TL;DR: Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects, as well as other related antidepressants for the treatment of hot flashes.